Merck & Co., Inc. Share Price Euronext Paris
Equities
MRK
US58933Y1055
Pharmaceuticals
Sales 2024 * | 64.18B 59.87B 5,359B | Sales 2025 * | 68.68B 64.08B 5,735B | Capitalization | 328B 306B 27,384B |
---|---|---|---|---|---|
Net income 2024 * | 19.51B 18.2B 1,629B | Net income 2025 * | 22.25B 20.76B 1,858B | EV / Sales 2024 * | 5.4 x |
Net Debt 2024 * | 18.6B 17.36B 1,553B | Net Debt 2025 * | 7.28B 6.79B 608B | EV / Sales 2025 * | 4.88 x |
P/E ratio 2024 * |
16.7
x | P/E ratio 2025 * |
14.5
x | Employees | 71,000 |
Yield 2024 * |
2.39% | Yield 2025 * |
2.53% | Free-Float | 70.77% |
Latest transcript on Merck & Co., Inc.
Managers | Title | Age | Since |
---|---|---|---|
Robert Davis
CEO | Chief Executive Officer | 57 | 01/14/01 |
Director of Finance/CFO | 55 | 01/90/01 | |
Dave Williams
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tom Glocer
BRD | Director/Board Member | 63 | 27/07/27 |
Pamela Craig
BRD | Director/Board Member | 67 | 01/15/01 |
Inge Thulin
BRD | Director/Board Member | 69 | 01/18/01 |
1st Jan change | Capi. | |
---|---|---|
+50.70% | 791B | |
+41.50% | 630B | |
+8.79% | 298B | |
+17.47% | 246B | |
+0.20% | 225B | |
+9.96% | 218B | |
+3.68% | 160B | |
-4.38% | 156B | |
-3.16% | 116B |